Novartis has announced an agreement to acquire Avidity Biosciences, which will add three promising late-stage programs, including FSHD, to its neuroscience pipeline.
FSHD Europe appreciates Avidity’s pioneering contributions in advancing FSHD research and values the productive collaboration to date. We look forward to continuing our efforts with Novartis to accelerate the development of safe, effective, and accessible treatments for FSHD.
Read the full announcement on the Novartis website.